Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Reference is made to Targovax ASA's (the "Company") stock exchange announcement on 9 March 2023, in which the Company announced that it had requested Atlas Special Opportunities, LLC ("Atlas") to subscribe and pay for the first tranche of convertible bonds under the Investment Agreement entered into between Atlas and the Company, consisting of 15 convertible bonds.
Atlas has today, by a notice of conversion issued to Nordic Trustee AS, requested conversion of convertible bonds with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are convertible into 4,026,629 new shares in the Company at a conversion price of NOK 0.620867.
The Company's share capital will accordingly be increased by NOK 402,662.90 by the issuance of 4,026,629 new shares upon completion of the conversion by registration of the share capital increase in the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company's total share capital will be NOK 19,260,420.10, divided into 192,604,201 shares, each with a nominal value of NOK 0.10.